1.53
0.28 (22.40%)
| Penutupan Terdahulu | 1.25 |
| Buka | 1.25 |
| Jumlah Dagangan | 4,995,897 |
| Purata Dagangan (3B) | 1,517,495 |
| Modal Pasaran | 177,910,992 |
| Harga / Jualan (P/S) | 22.16 |
| Harga / Buku (P/B) | 0.700 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| Margin Operasi (TTM) | -2,534.07% |
| EPS Cair (TTM) | -1.49 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -15.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.89% |
| Nisbah Semasa (MRQ) | 8.81 |
| Aliran Tunai Operasi (OCF TTM) | -123.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -76.88 M |
| Pulangan Atas Aset (ROA TTM) | -23.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Fate Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.40 |
|
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.74% |
| % Dimiliki oleh Institusi | 94.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wilshire Advisors Llc | 30 Sep 2025 | 8,486,822 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |